Sumitomo Dainippon Pharma Annual Report 2017
81/102

(C) Maturity analysis for monetary claims and marketable securities and investment in securities¥ —————¥ —Millions of yenWithin 1 yearFrom 5 yearsto 10 yearsOver 10 years¥ —————¥ —From 1 year to 5 years¥ —————¥ —¥ 71,4092,670109,02916,8194,000¥ 203,9272017Cash and time depositsTrade notesTrade accounts Due from parent company, unconsolidated subsidiaries and afliates Marketable securities and investment securities: Available-for-sale securities with terms of maturity (Negotiable certicates of deposit) Total ¥ —————¥ —Millions of yenWithin 1 yearFrom 5 yearsto 10 yearsOver 10 years¥ —————¥ —From 1 year to 5 years¥ —————¥ —¥ 54,9232,512105,31648,51311,100¥ 222,3642016Cash and time deposits Trade notes Trade accounts Due from parent company, unconsolidated subsidiaries and afliates Marketable securities and investment securities: Available-for-sale securities with terms of maturity (Negotiable certicates of deposit) Total $ —————$ —Thousands of U.S. dollarsWithin 1 yearFrom 5 yearsto 10 yearsOver 10 years$ —————$ —From 1 year to 5 years$ —————$ —$ 637,58023,839973,473150,17035,714$ 1,820,7762017Cash and time depositsTrade notesTrade accountsDue from parent company, unconsolidated subsidiaries and afliatesMarketable securities and investment securities: Available-for-sale securities with terms of maturity (Negotiable certicates of deposit) Total 80Sumitomo Dainippon Pharma Co., Ltd. Annual Report 2017

元のページ  ../index.html#81

このブックを見る